CTMS and Study Tracking
CTMS capabilities track studies, sites, enrollment, milestones, and deliverables, giving clinical operations a current picture rather than a reconstructed one.
Custom Software
Pharma Clinical Operations Software Development
Pharma clinical operations software manages trial execution across CTMS, eTMF, site management, and monitoring workflow, integrating with EDC and safety systems while maintaining the validation, audit trails, and data integrity that GCP and 21 CFR Part 11 require. Blinding integrity is enforced architecturally, not by access policy alone.
Clinical operations systems are inspected, which changes how they must be built: an eTMF that is complete but not demonstrably complete fails an inspection just as surely as one with missing documents. Taction Software builds pharma clinical operations software where validation documentation, audit trails, and inspection readiness are engineering deliverables produced alongside the system.
Tell Us Your Requirements
Our experts are ready to understand your business goals.
Trusted Partners
Trusted by Industry Leaders Worldwide
Recognition
Awards & Recognitions
What Is Pharma Clinical Operations Software
Pharma clinical operations software spans the systems running trial execution: CTMS for study, site, and milestone tracking, eTMF for regulated document management, site management and payment workflow, monitoring and risk-based oversight tooling, and integration with EDC, IRT, and safety databases. What distinguishes it from general project software is that its records are regulatory evidence subject to inspection, and its controls must prevent unblinding. Our work sits within our broader pharma and life sciences practice.
eTMF and Document Control
eTMF manages regulated documentation against the TMF Reference Model, with completeness tracking that supports inspection rather than only storing files.
Site Management and Payments
Site management covers activation tracking, contracts, and milestone-based payments, which frequently delay startup more than any scientific factor.
Monitoring and Risk-Based Oversight
Risk-based monitoring tooling prioritizes site visits using enrollment, deviation, and query patterns, with monitoring decisions made by clinical operations.
EDC and Safety Integration
Integration connects EDC, IRT, and safety systems so operational data flows without manual reconciliation across disconnected trial platforms.
Blinding and Access Integrity
Blinding integrity is enforced through data architecture and role separation, since accidental unblinding through an operational report compromises a study.
Core Pharma Clinical Operations Services
Our pharma clinical operations services cover CTMS and eTMF development, integration, monitoring tooling, validation delivery, and inspection support. Validation is scoped as a distinct workstream rather than folded into development, because computer system validation for GxP systems carries documentation obligations that materially affect timeline and cost. Engagements typically open with a review of current system landscape, validation posture, and inspection history. Deliverables are structured so clinical operations, data management, and quality assurance can review independently.
01
CTMS Development and Extension
We build or extend CTMS capability where commercial platforms constrain your operating model, integrating with existing trial infrastructure rather than replacing it.
02
eTMF and Reference Model Alignment
TMF Reference Model alignment structures documents for inspection, with completeness and timeliness metrics visible throughout the study rather than at closeout.
03
Trial Systems Integration
Integration spans EDC, IRT, and safety platforms, drawing on our enterprise application integration practice for system connectivity.
04
Risk-Based Monitoring Tooling
Monitoring analytics surface site risk signals for clinical operations review, complementing our clinical trials AI work on trial data.
05
Part 11 Validation Delivery
Systems supporting regulatory submissions require validation. Our 21 CFR Part 11 for AI work covers audit trails and computer system validation.
06
Inspection Readiness Support
We build inspection readiness reporting so TMF completeness and system controls can be demonstrated rather than asserted during an audit.
Benefits of Pharma Clinical Operations Software
The benefits concentrate in study visibility, inspection readiness, and reduced manual reconciliation across trial systems. Clinical operations teams routinely maintain spreadsheets alongside their systems because the systems do not answer their actual questions, and that shadow tracking is where errors and inspection findings originate. We publish no figures on enrollment speed, cycle time, or monitoring efficiency, because those depend entirely on your protocol, therapeutic area, and site network.
Current Study Visibility
Consolidated study tracking replaces the spreadsheets clinical operations maintain alongside official systems, which is where reconciliation errors originate.
Demonstrable Inspection Readiness
TMF completeness tracked throughout the study means readiness can be demonstrated on request rather than assembled during pre-inspection panic.
Reduced Manual Reconciliation
Integration removes duplicate entry across CTMS, EDC, and safety systems, which consumes clinical operations time and introduces discrepancies.
Faster Site Activation Visibility
Tracking activation bottlenecks shows where startup actually stalls, which is frequently contracting and budget rather than regulatory review.
Better Monitoring Allocation
Risk signals direct monitoring effort toward sites where oversight matters, with visit decisions made by clinical operations leadership.
Continuity Into Evidence Generation
Structured trial data supports downstream work, connecting with real world evidence platform capabilities post-approval.
Our Pharma Clinical Operations Process
We deliver pharma clinical operations projects in gated phases so clinical, data management, and quality stakeholders approve direction before engineering cost accumulates. Discovery establishes system landscape, validation scope, and inspection requirements. Validation planning happens before development rather than after, since retrofitting documentation to a built system is both expensive and less defensible. Blinding requirements are specified in architecture design, because unblinding risk is easiest to prevent and hardest to remediate.
Discovery and Validation Scoping
Discovery defines system scope and validation requirements, since GxP obligations shape architecture and materially affect timeline and cost.
Blinding Architecture Design
Blinding requirements are designed into data architecture and role separation before development, since accidental unblinding cannot be remediated after it occurs.
System Development
Development proceeds iteratively with clinical operations review, maintaining traceability from requirement through test as validation documentation accumulates.
Integration Delivery
Integration with EDC and safety systems is built and tested against vendor interfaces, which vary considerably in capability and documentation quality.
Computer System Validation
Validation follows IQ, OQ, PQ protocols with documented testing, traceability matrices, and change control appropriate to the system’s regulatory role.
Deployment and Inspection Support
Deployment includes inspection support materials, so system controls and validation evidence are ready before an inspector requests them.
Technology and Compliance
Clinical operations systems fall under GCP, 21 CFR Part 11, and applicable regional requirements including EU Annex 11 for studies conducted internationally. Taction holds ISO 27001 certification. Part 11 requires audit trails, electronic signature controls, and computer system validation, while data integrity expectations summarized as ALCOA principles govern how records must be attributable, legible, contemporaneous, original, and accurate. Blinding integrity deserves separate emphasis, since an operational report exposing treatment assignment can compromise study validity irreversibly.
21 CFR Part 11 Compliance
Part 11 requires audit trails, electronic signatures, and validation, which shape architecture from the first design decision rather than after.
Data Integrity Principles
ALCOA expectations govern record attributability, contemporaneity, and accuracy, which affects how edits, versions, and corrections are handled technically.
Blinding Integrity Controls
Unblinding risk is addressed through data architecture and role separation, since a single operational report can compromise study validity permanently.
GCP Alignment
GCP expectations govern documentation, monitoring, and site oversight, informing workflow design rather than sitting adjacent to it as policy.
Validation Documentation
Computer system validation produces IQ, OQ, and PQ evidence with traceability, delivered as a work product rather than assembled before inspection.
Deployment Security
Deployments run in your cloud tenancy or hybrid, with network segmentation, signed container images, and documented penetration testing before release.
Why Choose Taction Software
Taction Software was founded in 2013 and has spent over 12 years building healthcare and life sciences software, delivering more than 200 healthcare projects from four US offices in Chicago, Cheyenne, Austin, and Sacramento, with ISO 27001 certification. Our relevant discipline here is treating validation as a workstream with its own cost rather than as documentation produced at the end. Systems validated retrospectively are both more expensive and less defensible under inspection. Our leadership brings more than 20 years of personal experience in the field.
01
Validation as a Workstream
We scope computer system validation explicitly with its own timeline and cost, since retrofitting documentation is expensive and less defensible.
02
Blinding Designed In
Blinding integrity is addressed in architecture rather than access policy, because unblinding is the one failure that cannot be remediated afterward.
03
Established Healthcare Focus
Founded in 2013, we have concentrated on healthcare and life sciences rather than treating them as one vertical among several.
04
Trial Systems Integration
We integrate EDC, IRT, and safety platforms, handling vendor interface variability that makes clinical operations integration harder than it appears.
05
Inspection-Oriented Delivery
We build inspection readiness reporting into the system, so completeness and controls can be demonstrated rather than asserted under audit.
06
Certified Security Posture
ISO 27001 certification means security controls are documented and auditable, supporting sponsor and CRO vendor qualification efficiently.
Pricing
Pharma clinical operations software pricing depends on scope, validation requirements, integration breadth, and whether you are building or extending. Validation typically represents a substantial share of total cost for GxP systems, and we scope it separately so that share is visible rather than buried. Discovery produces an itemized, fixed-scope estimate with phase-level breakdown. Platform licensing, EDC and IRT vendor fees, and cloud infrastructure are separate from engineering cost and itemized clearly.
MVP or Single Module
An MVP covering site management or a focused CTMS capability typically runs $40,000 to $80,000, including proportionate validation documentation.
Full Platform Build
A full platform with CTMS, eTMF, monitoring tooling, and trial system integration typically falls between $80,000 and $200,000.
Enterprise Deployment
Enterprise engagements covering portfolio deployment, full Part 11 validation, and multi-sponsor segregation start at $200,000.
Discovery and Validation Planning
Discovery is a paid, time-boxed phase producing an itemized estimate, architecture plan, and validation scope assessment reviewed with quality assurance.
Cost Drivers to Expect
Validation scope, integration count, blinding complexity, and portfolio breadth are the largest variables, identified during discovery for budget planning.
Ongoing Support Costs
Post-launch revalidation, regulatory updates, integration maintenance, and support are quoted separately as a retainer sized to active study count.
Get Started
If you are evaluating pharma clinical operations software for CTMS, eTMF, site management, or monitoring workflow, the fastest next step is a discovery call with our team. We will review your system landscape, scope validation requirements with your quality function, and return an itemized, fixed-scope estimate. Contact us to schedule that conversation.
FAQs
Frequently Asked Questions
Clinical operations and quality leaders evaluating pharma clinical operations software usually ask about validation cost, whether building is justified against commercial platforms, and how blinding is protected. The answers below reflect how we scope these projects.
Substantially, and we scope it separately so it is visible. GxP systems supporting submissions require IQ, OQ, and PQ documentation with traceability and change control. Retrofitting that to a completed system costs more and defends worse under inspection, so we plan validation before development starts.
Buy, in most cases. Commercial CTMS platforms cover standard trial operations well. Building makes sense where your operating model, portfolio structure, or integration requirements genuinely exceed configuration limits, or where you need capability existing platforms do not provide. We assess this honestly in discovery.
Through data architecture and role separation designed before development, not through access permissions applied afterward. Treatment assignment data is structurally unavailable to operational reporting paths. Unblinding is the one integrity failure that cannot be remediated, so we prevent it at design rather than detect it later.
An MVP runs $40,000 to $80,000. A full platform typically falls between $80,000 and $200,000. Enterprise portfolio deployments with full validation start at $200,000. Validation scope is the largest variable and is quoted explicitly rather than folded into development.
Usually yes, though capability varies considerably by vendor and contract. Some EDC platforms expose well-documented APIs, others provide limited export. We verify what your specific platform and agreement permit during discovery rather than assuming integration depth that may not be available.
Yes, by tracking TMF completeness and timeliness throughout the study rather than at closeout, and by producing validation evidence as a work product. Inspection readiness is a state you maintain rather than a project you run before an audit, and the system should support that continuously.